Institut Gustave Roussy;Institut National de la Sante et de la Recherche Medicale (INSERM);Universite Paris-Sud;Institut National de la Recherche Agronomique (INRA)
The present invention relates to the role of the microbiota in the efficacy of cancer treatments with a drug blocking an. immune checkpoint and provides methods and probiotics to improve the efficacy of such a treatment in patients in need thereof. More particularly, the invention pertains to the use of vancomycin or penicillin to modulate the gut microbiota to potentiate the anticancer effects of anti-CTLA4 molecules.